Author: Site Editor Publish Time: 2026-09-04 Origin: Site
On August 21, 2026, the U.S. Food and Drug Administration (FDA) issued 55 draft Product-Specific Guidances (PSGs) for generic drug development. The package includes 24 new PSGs and 31 revised guidances, with 18 addressing complex drug products.
The latest PSGs are intended to provide more specific recommendations on the development and evidence requirements for abbreviated new drug applications (ANDAs), supporting more efficient generic drug development and regulatory review. According to the FDA, the initiative is part of its broader efforts to promote pharmaceutical competition and implement Executive Order 14273, with the aim of accelerating generic drug development and approval.
More than 30 of the newly issued or revised PSGs cover products for which no ANDA has yet been approved. Among them, 15 relate to complex drug products, providing developers with greater clarity on potential development and bioequivalence (BE) strategies.
The package includes guidance for emerging and technically challenging products, such as a dipeptidyl peptidase 1 (DPP1) inhibitor that represents the first approved treatment for non-cystic fibrosis bronchiectasis.
The FDA also issued a new PSG for benzoyl peroxide/tretinoin topical cream. Rather than relying on comparative clinical endpoint studies, the draft guidance recommends an approach based on in vitro BE studies and product characterization, potentially reducing the need for more resource-intensive clinical studies.
On the same day, the FDA also updated its list of upcoming PSGs, providing visibility into products expected to receive new or revised guidance over the next 12 months, together with anticipated publication timelines and revision categories.
Of particular importance is the Critical revision category, which may have implications for all ANDAs, including previously approved applications. The FDA notes that holders of approved ANDAs should monitor relevant revisions and assess whether changes in safety or efficacy considerations require further action.
For generic drug developers, these updates provide an important opportunity to incorporate FDA-specific expectations at an earlier stage of product selection and development. Understanding the recommended BE approaches, supporting evidence, and potential regulatory changes can help companies reduce uncertainty in development planning and optimize their regulatory strategies.
The latest FDA PSG updates reinforce the increasing importance of regulatory intelligence in generic drug development, particularly for complex products where the appropriate BE pathway and supporting evidence can significantly influence development timelines, costs, and approval prospects.
For companies pursuing international generic drug strategies, early assessment of regulatory requirements can also support better decisions regarding product selection, development pathways, BE study design, registration sequencing, and commercialization planning.
Biocom will continue to monitor FDA PSGs and other major regulatory developments, evaluate their potential impact on generic drug development, bioequivalence strategies, and ANDA submissions, and incorporate relevant regulatory and technical insights into our R&D and registration services.
Through regulatory intelligence and integrated pharmaceutical development capabilities, Biocom supports global partners in making informed development and registration decisions and advancing generic products toward international markets.
